哌甲酯治疗阿尔茨海默病淡漠的随机临床试验
ADMET 2 多中心随机安慰剂对照试验纳入 200 例伴中重度淡漠的阿尔茨海默病患者,评估哌甲酯 10 mg 每日两次治疗 6 个月的效果。
要点
- 哌甲酯 10 mg 每日两次可显著降低阿尔茨海默病患者的 NPI 淡漠评分。
- 淡漠改善主要出现在治疗前 100 天内,无淡漠症状比例显著高于安慰剂。
- 认知功能与生活质量未见显著组间差异,严重不良事件与研究药物无关。
核心结论
- 哌甲酯是治疗阿尔茨海默病淡漠安全有效的药物。
研究设计与样本
- 多中心随机安慰剂对照临床试验,2016 年 8 月至 2020 年 7 月在美国 9 家和加拿大 1 家痴呆专科门诊开展。
- 共筛查 307 例潜在参与者,最终 200 例阿尔茨海默病伴轻中度认知障碍及频繁和/或严重淡漠者入组,99 例接受哌甲酯、101 例接受安慰剂。
主要发现
- 认知指标与生活质量组间无显著差异;17 例严重不良事件均与研究药物无关,安全性无显著组间差异。
临床怎么用
- 对于阿尔茨海默病伴频繁和/或严重淡漠的患者,可考虑使用哌甲酯 10 mg 每日两次治疗。
- 治疗早期即可观察到淡漠改善,需关注前 100 天内的疗效评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Apathy, characterized by diminished will or initiative and one of the most prevalent neuropsychiatric symptoms in individuals with Alzheimer disease, is associated with significant caregiver burden, excess disability, increased medical costs, and mortality. OBJECTIVE: To measure whether methylphenidate compared with placebo decreases the severity of apathy in individuals with Alzheimer disease. DESIGN, SETTING, AND PARTICIPANTS: This multicenter randomized placebo-controlled clinical trial was conducted from August 2016 to July 2020 in 9 US clinics and 1 Canadian clinic specializing in dementia care. A total of 307 potential participants were screened. Of those, 52 did not pass screening and 55 were not eligible. Participants with Alzheimer disease, mild to moderate cognitive impairment, and frequent and/or severe apathy as measured by the Neuropsychiatric Inventory (NPI) were included. INTERVENTIONS: Ten milligrams of methylphenidate, twice daily, vs matching placebo. MAIN OUTCOMES AND MEASURES: The coprimary outcomes included (1) change from baseline to 6 months in the NPI apathy subscale or (2) improved rating on the Alzheimer's Disease Cooperative Study Clinical Global Impression of Change. Other outcomes include safety, change in cognition, and quality of life. RESULTS: Of 200 participants, 99 were assigned to methylphenidate and 101 to placebo. The median (interquartile range) age of study participants was 76 (71-81) years; 68 (34%) were female and 131 (66%) were male. A larger decrease was found from baseline to 6 months in the NPI apathy score in those receiving methylphenidate compared with placebo (mean difference, -1.25; 95% CI, -2.03 to -0.47; P = .002). The largest decrease in the NPI apathy score was observed in the first 100 days, with a significant hazard ratio for the proportion of participants with no apathy symptoms receiving methylphenidate compared with placebo (hazard ratio, 2.16; 95% CI, 1.19-3.91; P = .01). At 6 months, the odds ratio of having an improved rating on the Alzheimer's Disease Cooperative Study Clinical Global Impression of Change for methylphenidate compared with placebo was 1.90 (95% CI, 0.95-3.84; P = .07). The difference in mean change from baseline to 6 months estimated using a longitudinal model was 1.43 (95% CI, 1.00-2.04; P = .048). Cognitive measures and quality of life were not significantly different between groups. Of the 17 serious adverse events that occurred during the study, none were related to the study drug. No significant differences in the safety profile were noted between treatment groups. CONCLUSIONS AND RELEVANCE: This study found methylphenidate to be a safe and efficacious medication to use in the treatment of apathy in Alzheimer disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02346201.
引用
- Mintzer J, Lanctôt KL, Scherer RW, et al. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol. 2021. PMID: 34570180. doi:10.1001/jamaneurol.2021.3356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。